# Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)

> **NCT00314509** · PHASE2 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 240 (—)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Ciclesonide/Formoterol Combination

## Key facts

- **NCT ID:** NCT00314509
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 240 (—)
- **Last updated:** 2016-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00314509

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00314509, "Safety and Tolerability of Ciclesonide and Formoterol Fumarate Inhaled Once Daily in Patients With Asthma (18 to 75 y) (BY9010/M1-506)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00314509. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*